Percheron Therapeutics (ASX:PER) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PER Overzicht aandelen

Percheron Therapeutics Limited houdt zich bezig met onderzoek naar en ontwikkeling van nieuwe antisense geneesmiddelen in Australië.

Over het bedrijf

PER fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 22.9% per jaar dalen.

Heeft geen betekenisvolle marktkapitalisatie ( A$90M )

Heeft geen zinvolle omzet ( A$3M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Percheron Therapeutics Limited Concurrenten

Recce Pharmaceuticals

ASX:RCE

AU$117.0m

Vitura Health

ASX:VIT

AU$42.0m

Argenica Therapeutics

ASX:AGN

AU$87.1m

Starpharma Holdings

ASX:SPL

AU$41.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Percheron Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.10
52 Week Hoogtepunt	AU$0.12
52 Week Laag	AU$0.052
Bèta	0.87
11 maand verandering	17.65%
3 maanden verandering	17.65%
1 Jaar Verandering	38.89%
33 jaar verandering	-50.00%
5 jaar verandering	2.04%
Verandering sinds IPO	-95.83%

Recent nieuws en updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

Rendement voor aandeelhouders

	PER	AU Pharmaceuticals	AU Markt
7D	1.0%	3.8%	1.1%
1Y	38.9%	98.5%	17.9%

Rendement versus industrie: PER presteerde slechter dan de Australian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 98.5 % opleverde.

Rendement versus markt: PER overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 17.9 %.

Prijsvolatiliteit

Is PER's price volatile compared to industry and market?
PER volatility
PER Average Weekly Movement	7.7%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.6%

Stabiele aandelenkoers: De aandelenkoers van PER is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van PER is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	n/a	James Garner	www.PercheronTx.com

Percheron Therapeutics Limited houdt zich bezig met onderzoek naar en ontwikkeling van nieuwe antisense geneesmiddelen in Australië. De productpijplijn van het bedrijf omvat ATL1102, een antisense inhibitor van CD49d, dat zich in Fase IIa klinische studie bevindt voor de behandeling van Duchenne spierdystrofie, Limb Girdle spierdystrofie R2, multiple sclerose, astma en andere inflammatoire indicaties. De productpijplijn omvat ook Atesidorsen (ATL1103), een oligonucleotide gericht tegen de groeihormoonreceptor die ontworpen is om de expressie van de groeihormoonreceptor te blokkeren en zo de niveaus van het hormoon insuline-achtige groeifactor-I in het bloed te verlagen, alsook om ziekten te behandelen die geassocieerd worden met overmatige groeihormoonwerking en die Fase II van de klinische studie heeft voltooid.

Percheron Therapeutics Limited Samenvatting

Hoe verhouden de winst en inkomsten van Percheron Therapeutics zich tot de beurswaarde?
PER fundamentele statistieken
Marktkapitalisatie	AU$90.15m
Inkomsten(TTM)	-AU$11.92m
Inkomsten(TTM)	AU$2.97m

30.4x

P/S-verhouding

-7.6x

Koers/Winstverhouding

Is PER overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PER resultatenrekening (TTM)
Inkomsten	AU$2.97m
Kosten van inkomsten	AU$62.15k
Brutowinst	AU$2.91m
Overige uitgaven	AU$14.83m
Inkomsten	-AU$11.92m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.013
Brutomarge	97.91%
Nettowinstmarge	-401.57%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde PER op de lange termijn?

Bekijk historische prestaties en vergelijking

PER Overzicht aandelen

Beloningen

Risicoanalyse

Percheron Therapeutics Limited Concurrenten

ASX:RCE

AU$117.0m

ASX:VIT

AU$42.0m

ASX:AGN

AU$87.1m

ASX:SPL

AU$41.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Consensus revenue estimates decrease by 40%

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Recent updates

Consensus revenue estimates decrease by 40%

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Percheron Therapeutics Limited Samenvatting